Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants
Objective To investigate the use of nebulized 3% hypertonic saline (HS) for treating viral bronchiolitis in moderately ill hospitalized infants by a prospective, randomized, double-blinded, controlled, multicenter trial. Study design A total of 96 infants (mean age, 4.7 months; range, 0.3 to 18 mont...
Gespeichert in:
| Veröffentlicht in: | The Journal of pediatrics 2007-09, Vol.151 (3), p.266-270.e1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 270.e1 |
|---|---|
| container_issue | 3 |
| container_start_page | 266 |
| container_title | The Journal of pediatrics |
| container_volume | 151 |
| creator | Kuzik, Brian A., MD, MSc, FRCP(C) Al Qadhi, Samim A., MD, MBChB Kent, Steven, BSc(med), MD, FRCP(C) Flavin, Michael P., MB, MRCP(UK), FRCP(C) Hopman, Wilma, MA Hotte, Simon, MD Gander, Sarah, MD |
| description | Objective To investigate the use of nebulized 3% hypertonic saline (HS) for treating viral bronchiolitis in moderately ill hospitalized infants by a prospective, randomized, double-blinded, controlled, multicenter trial. Study design A total of 96 infants (mean age, 4.7 months; range, 0.3 to 18 months) admitted to the hospital for treatment of viral bronchiolitis were recruited from 3 regional pediatric centers over 3 bronchiolitis seasons (December 2003 to May 2006). Patients were randomized to receive, in a double-blind fashion, repeated doses of nebulized 3% HS (treatment group) or 0.9% normal saline (NS; control group), in addition to routine therapy ordered by the attending physician. The principal outcome measure was hospital length of stay (LOS). Results On an intention-to-treat basis, the infants in the HS group had a clinically relevant 26% reduction in LOS to 2.6 ± 1.9 days, compared with 3.5 ± 2.9 days in the NS group ( P = .05). The treatment was well tolerated, with no adverse effects attributable to the use of HS. Conclusions The use of nebulized 3% HS is a safe, inexpensive, and effective treatment for infants hospitalized with moderately severe viral bronchiolitis. |
| doi_str_mv | 10.1016/j.jpeds.2007.04.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68200807</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347607003459</els_id><sourcerecordid>68200807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-e4e3e7afe73f76fb2b2f9f76109daff5e3f0d5bc58f651d9bde68a1b6a2e21483</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvLL0BCucAt6fgjdnIACSqglapyaMvVcpyx6pB1FjtBWn49DrtSJS49eQ7POx49LyFvKFQUqDwfqmGHfaoYgKpAVEDhGdlQaFUpG86fkw0AYyUXSp6QVykNANAKgJfkhCpF25bXG3Jzg90y-j_YF5f7HcZ5Ct4Wt2b0AQsfivkBi7uIZt5imIvJFT98NGPxOU7BPvhp9LNPK3cVnAlzOiMvnBkTvj6-p-T-65e7i8vy-vu3q4tP16UVgs0lCuSojEPFnZKuYx1zbZ7y8b1xrkbuoK87WzdO1rRvux5lY2gnDUNGRcNPyfvD3l2cfi2YZr31yeI4moDTkrRsspUGVAb5AbRxSimi07votybuNQW9atSD_qdRrxo1CJ015tTb4_ql22L_mDl6y8C7I2CSNaOLJlifHrm2kbIGmrkPBw6zjN8eo07WY7DY-4h21v3knzjk4395m5vx-cufuMc0TEsM2bOmOjEN-nZtfC0cFAAXdcv_AuYspxs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68200807</pqid></control><display><type>article</type><title>Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kuzik, Brian A., MD, MSc, FRCP(C) ; Al Qadhi, Samim A., MD, MBChB ; Kent, Steven, BSc(med), MD, FRCP(C) ; Flavin, Michael P., MB, MRCP(UK), FRCP(C) ; Hopman, Wilma, MA ; Hotte, Simon, MD ; Gander, Sarah, MD</creator><creatorcontrib>Kuzik, Brian A., MD, MSc, FRCP(C) ; Al Qadhi, Samim A., MD, MBChB ; Kent, Steven, BSc(med), MD, FRCP(C) ; Flavin, Michael P., MB, MRCP(UK), FRCP(C) ; Hopman, Wilma, MA ; Hotte, Simon, MD ; Gander, Sarah, MD</creatorcontrib><description>Objective To investigate the use of nebulized 3% hypertonic saline (HS) for treating viral bronchiolitis in moderately ill hospitalized infants by a prospective, randomized, double-blinded, controlled, multicenter trial. Study design A total of 96 infants (mean age, 4.7 months; range, 0.3 to 18 months) admitted to the hospital for treatment of viral bronchiolitis were recruited from 3 regional pediatric centers over 3 bronchiolitis seasons (December 2003 to May 2006). Patients were randomized to receive, in a double-blind fashion, repeated doses of nebulized 3% HS (treatment group) or 0.9% normal saline (NS; control group), in addition to routine therapy ordered by the attending physician. The principal outcome measure was hospital length of stay (LOS). Results On an intention-to-treat basis, the infants in the HS group had a clinically relevant 26% reduction in LOS to 2.6 ± 1.9 days, compared with 3.5 ± 2.9 days in the NS group ( P = .05). The treatment was well tolerated, with no adverse effects attributable to the use of HS. Conclusions The use of nebulized 3% HS is a safe, inexpensive, and effective treatment for infants hospitalized with moderately severe viral bronchiolitis.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/j.jpeds.2007.04.010</identifier><identifier>PMID: 17719935</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Administration, Inhalation ; Biological and medical sciences ; Bronchiolitis, Viral - drug therapy ; Bronchodilator Agents - therapeutic use ; Chronic obstructive pulmonary disease, asthma ; Double-Blind Method ; Drug Therapy, Combination ; Female ; General aspects ; Humans ; Infant ; Infant, Newborn ; Length of Stay ; Male ; Medical sciences ; Oxygen - blood ; Pediatrics ; Pneumology ; Prospective Studies ; Saline Solution, Hypertonic - administration & dosage</subject><ispartof>The Journal of pediatrics, 2007-09, Vol.151 (3), p.266-270.e1</ispartof><rights>Mosby, Inc.</rights><rights>2007 Mosby, Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-e4e3e7afe73f76fb2b2f9f76109daff5e3f0d5bc58f651d9bde68a1b6a2e21483</citedby><cites>FETCH-LOGICAL-c442t-e4e3e7afe73f76fb2b2f9f76109daff5e3f0d5bc58f651d9bde68a1b6a2e21483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jpeds.2007.04.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19866501$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17719935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuzik, Brian A., MD, MSc, FRCP(C)</creatorcontrib><creatorcontrib>Al Qadhi, Samim A., MD, MBChB</creatorcontrib><creatorcontrib>Kent, Steven, BSc(med), MD, FRCP(C)</creatorcontrib><creatorcontrib>Flavin, Michael P., MB, MRCP(UK), FRCP(C)</creatorcontrib><creatorcontrib>Hopman, Wilma, MA</creatorcontrib><creatorcontrib>Hotte, Simon, MD</creatorcontrib><creatorcontrib>Gander, Sarah, MD</creatorcontrib><title>Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>Objective To investigate the use of nebulized 3% hypertonic saline (HS) for treating viral bronchiolitis in moderately ill hospitalized infants by a prospective, randomized, double-blinded, controlled, multicenter trial. Study design A total of 96 infants (mean age, 4.7 months; range, 0.3 to 18 months) admitted to the hospital for treatment of viral bronchiolitis were recruited from 3 regional pediatric centers over 3 bronchiolitis seasons (December 2003 to May 2006). Patients were randomized to receive, in a double-blind fashion, repeated doses of nebulized 3% HS (treatment group) or 0.9% normal saline (NS; control group), in addition to routine therapy ordered by the attending physician. The principal outcome measure was hospital length of stay (LOS). Results On an intention-to-treat basis, the infants in the HS group had a clinically relevant 26% reduction in LOS to 2.6 ± 1.9 days, compared with 3.5 ± 2.9 days in the NS group ( P = .05). The treatment was well tolerated, with no adverse effects attributable to the use of HS. Conclusions The use of nebulized 3% HS is a safe, inexpensive, and effective treatment for infants hospitalized with moderately severe viral bronchiolitis.</description><subject>Administration, Inhalation</subject><subject>Biological and medical sciences</subject><subject>Bronchiolitis, Viral - drug therapy</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Oxygen - blood</subject><subject>Pediatrics</subject><subject>Pneumology</subject><subject>Prospective Studies</subject><subject>Saline Solution, Hypertonic - administration & dosage</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EokvLL0BCucAt6fgjdnIACSqglapyaMvVcpyx6pB1FjtBWn49DrtSJS49eQ7POx49LyFvKFQUqDwfqmGHfaoYgKpAVEDhGdlQaFUpG86fkw0AYyUXSp6QVykNANAKgJfkhCpF25bXG3Jzg90y-j_YF5f7HcZ5Ct4Wt2b0AQsfivkBi7uIZt5imIvJFT98NGPxOU7BPvhp9LNPK3cVnAlzOiMvnBkTvj6-p-T-65e7i8vy-vu3q4tP16UVgs0lCuSojEPFnZKuYx1zbZ7y8b1xrkbuoK87WzdO1rRvux5lY2gnDUNGRcNPyfvD3l2cfi2YZr31yeI4moDTkrRsspUGVAb5AbRxSimi07votybuNQW9atSD_qdRrxo1CJ015tTb4_ql22L_mDl6y8C7I2CSNaOLJlifHrm2kbIGmrkPBw6zjN8eo07WY7DY-4h21v3knzjk4395m5vx-cufuMc0TEsM2bOmOjEN-nZtfC0cFAAXdcv_AuYspxs</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Kuzik, Brian A., MD, MSc, FRCP(C)</creator><creator>Al Qadhi, Samim A., MD, MBChB</creator><creator>Kent, Steven, BSc(med), MD, FRCP(C)</creator><creator>Flavin, Michael P., MB, MRCP(UK), FRCP(C)</creator><creator>Hopman, Wilma, MA</creator><creator>Hotte, Simon, MD</creator><creator>Gander, Sarah, MD</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070901</creationdate><title>Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants</title><author>Kuzik, Brian A., MD, MSc, FRCP(C) ; Al Qadhi, Samim A., MD, MBChB ; Kent, Steven, BSc(med), MD, FRCP(C) ; Flavin, Michael P., MB, MRCP(UK), FRCP(C) ; Hopman, Wilma, MA ; Hotte, Simon, MD ; Gander, Sarah, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-e4e3e7afe73f76fb2b2f9f76109daff5e3f0d5bc58f651d9bde68a1b6a2e21483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Inhalation</topic><topic>Biological and medical sciences</topic><topic>Bronchiolitis, Viral - drug therapy</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Oxygen - blood</topic><topic>Pediatrics</topic><topic>Pneumology</topic><topic>Prospective Studies</topic><topic>Saline Solution, Hypertonic - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuzik, Brian A., MD, MSc, FRCP(C)</creatorcontrib><creatorcontrib>Al Qadhi, Samim A., MD, MBChB</creatorcontrib><creatorcontrib>Kent, Steven, BSc(med), MD, FRCP(C)</creatorcontrib><creatorcontrib>Flavin, Michael P., MB, MRCP(UK), FRCP(C)</creatorcontrib><creatorcontrib>Hopman, Wilma, MA</creatorcontrib><creatorcontrib>Hotte, Simon, MD</creatorcontrib><creatorcontrib>Gander, Sarah, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuzik, Brian A., MD, MSc, FRCP(C)</au><au>Al Qadhi, Samim A., MD, MBChB</au><au>Kent, Steven, BSc(med), MD, FRCP(C)</au><au>Flavin, Michael P., MB, MRCP(UK), FRCP(C)</au><au>Hopman, Wilma, MA</au><au>Hotte, Simon, MD</au><au>Gander, Sarah, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>151</volume><issue>3</issue><spage>266</spage><epage>270.e1</epage><pages>266-270.e1</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>Objective To investigate the use of nebulized 3% hypertonic saline (HS) for treating viral bronchiolitis in moderately ill hospitalized infants by a prospective, randomized, double-blinded, controlled, multicenter trial. Study design A total of 96 infants (mean age, 4.7 months; range, 0.3 to 18 months) admitted to the hospital for treatment of viral bronchiolitis were recruited from 3 regional pediatric centers over 3 bronchiolitis seasons (December 2003 to May 2006). Patients were randomized to receive, in a double-blind fashion, repeated doses of nebulized 3% HS (treatment group) or 0.9% normal saline (NS; control group), in addition to routine therapy ordered by the attending physician. The principal outcome measure was hospital length of stay (LOS). Results On an intention-to-treat basis, the infants in the HS group had a clinically relevant 26% reduction in LOS to 2.6 ± 1.9 days, compared with 3.5 ± 2.9 days in the NS group ( P = .05). The treatment was well tolerated, with no adverse effects attributable to the use of HS. Conclusions The use of nebulized 3% HS is a safe, inexpensive, and effective treatment for infants hospitalized with moderately severe viral bronchiolitis.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>17719935</pmid><doi>10.1016/j.jpeds.2007.04.010</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 2007-09, Vol.151 (3), p.266-270.e1 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68200807 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Inhalation Biological and medical sciences Bronchiolitis, Viral - drug therapy Bronchodilator Agents - therapeutic use Chronic obstructive pulmonary disease, asthma Double-Blind Method Drug Therapy, Combination Female General aspects Humans Infant Infant, Newborn Length of Stay Male Medical sciences Oxygen - blood Pediatrics Pneumology Prospective Studies Saline Solution, Hypertonic - administration & dosage |
| title | Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A44%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nebulized%20Hypertonic%20Saline%20in%20the%20Treatment%20of%20Viral%20Bronchiolitis%20in%20Infants&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Kuzik,%20Brian%20A.,%20MD,%20MSc,%20FRCP(C)&rft.date=2007-09-01&rft.volume=151&rft.issue=3&rft.spage=266&rft.epage=270.e1&rft.pages=266-270.e1&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/j.jpeds.2007.04.010&rft_dat=%3Cproquest_cross%3E68200807%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68200807&rft_id=info:pmid/17719935&rft_els_id=S0022347607003459&rfr_iscdi=true |